文献速递神经肌肉病

早期无创通气治疗ALS的安慰剂对照先导试验

Trial of early noninvasive ventilation for ALS: A pilot placebo-controlled study.
PubMed 文献 · Neurology · 2016-08-31

这项单中心、前瞻性、双盲、随机、假对照先导试验在54例尚未达到指南推荐无创通气使用标准的ALS患者中比较了早期有创无创通气与假无创通气的耐受性和使用情况。结果显示两组无创通气使用时间无显著差异,但活跃组FVC下降速度更慢(组间差异0.44/月,p=0.049),生存和呼吸肌力变化无差异。结论认为早期无创通气的疗效需在随机安慰剂对照试验中进一步验证。

要点

  • 在尚未符合指南推荐标准的ALS患者中,早期无创通气与假无创通气的依从性相似。
  • 活跃无创通气组FVC下降速度较假组减慢(组间差异0.44/月,p=0.049)。
  • 两组生存率和最大吸气压/呼气压变化无显著差异。

核心结论

  • 早期无创通气在ALS患者中的疗效需通过随机安慰剂对照试验进一步验证。
  • 对于ALS患者,无创通气的依从性与假无创通气相似。

研究设计与样本

  • 单中心、前瞻性、双盲、随机、假对照先导试验。
  • 共随机分配54例尚未符合指南推荐无创通气使用标准的ALS患者。
  • 患者随机接受假无创通气或活跃无创通气,每约3个月进行主动监测直至FVC<50%或需无创通气管理临床症状。

主要发现

  • 假无创通气组平均每日使用时间为2.0小时(95%CI 1.1-3.0),活跃无创通气组为3.3小时(95%CI 2.0-4.6),组间无显著差异(p=0.347)。
  • 88%的假无创通气参与者和73%的活跃无创通气参与者报告使用无创通气仅轻微问题或无问题。
  • 治疗期间FVC变化组间差异为0.44/月,倾向于活跃无创通气(p=0.049)。
  • 两组生存率和最大吸气压或呼气压变化无差异。

临床怎么用

  • 对于尚未达到指南推荐标准的ALS患者,早期无创通气可能减缓FVC下降,但需进一步随机对照试验证实。
  • 临床使用无创通气时,患者耐受性普遍良好,依从性与假通气相似。

局限性

  • 本研究为单中心先导试验,样本量较小(54例),结果需更大规模试验验证。
  • 研究未报告长期生存获益或呼吸肌力改善的显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the use and tolerability of noninvasive positive pressure ventilation (NIV) in patients with amyotrophic lateral sclerosis (ALS) early in their disease by comparing active NIV and sham NIV in patients not yet eligible for NIV use as recommended by practice guidelines. METHODS: This was a single-center, prospective, double-blind, randomized, placebo (sham)-controlled pilot trial. Patients with ALS were randomized to receive either sham NIV or active NIV and underwent active surveillance approximately every 3 months until they reached a forced vital capacity (FVC) <50% or required NIV for clinical symptom management. RESULTS: In total, 54 participants were randomized. The mean NIV use was 2.0 hours (95% confidence interval [CI] 1.1-3.0) per day in the sham NIV treatment group and 3.3 hours (CI 2.0-4.6) per day in the active NIV group, which did not differ by treatment group (p = 0.347). The majority of sham NIV participants (88%) and active NIV participants (73%) reported only mild or no problem with NIV use. Difference of change in FVC through the treatment period by group (0.44 per month) favored active NIV (p = 0.049). Survival and changes in maximal inspiratory or expiratory pressure did not differ between treatment groups. CONCLUSIONS: The efficacy of early NIV in ALS should be tested in randomized, placebo-controlled trials. The trial is registered on clinicaltrials.gov (NCT00580593). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with ALS, adherence with NIV and sham NIV are similar.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Jacobs TL, Brown DL, Baek J, et al. Trial of early noninvasive ventilation for ALS: A pilot placebo-controlled study. Neurology. 2016. PMID: 27581221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。